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The caspase-8 inhibitor FLIP promotes activation of NF-κB and
Erk signaling pathways 
T. Kataoka*, R.C. Budd*†, N. Holler*, M. Thome*, F. Martinon*, M. Irmler*,
K. Burns*, M. Hahne*, N. Kennedy†, M. Kovacsovics* and J. Tschopp*
Background: Activation of Fas (CD95) by its ligand (FasL) rapidly induces cell
death through recruitment and activation of caspase-8 via the adaptor protein
Fas-associated death domain protein (FADD). However, Fas signals do not
always result in apoptosis but can also trigger a pathway that leads to
proliferation. We investigated the level at which the two conflicting Fas signals
diverge and the protein(s) that are implicated in switching the response. 
Results: Under conditions in which proliferation of CD3-activated human T
lymphocytes is increased by recombinant FasL, there was activation of the
transcription factors NF-κB and AP-1 and recruitment of the caspase-8 inhibitor
and FADD-interacting protein FLIP (FLICE-like inhibitory protein). Fas-recruited
FLIP interacts with TNF-receptor associated factors 1 and 2, as well as with
the kinases RIP and Raf-1, resulting in the activation of the NF-κB and
extracellular signal regulated kinase (Erk) signaling pathways. In T cells these
two signal pathways are critical for interleukin-2 production. Increased
expression of FLIP in T cells resulted in increased production of interleukin-2. 
Conclusions: We provide evidence that FLIP is not simply an inhibitor of
death-receptor-induced apoptosis but that it also mediates the activation of
NF-κB and Erk by virtue of its capacity to recruit adaptor proteins involved in
these signaling pathways.
Background
Members of the family of receptors for tumour necrosis
factor (TNF) and their ligands are critical regulators of
apoptosis and various other cellular processes. The recep-
tors have characteristic cysteine-rich motifs in the extracel-
lular domain. Their ligands are a family of type II
membrane glycoproteins with homology to TNF, but they
can also exist as soluble trimers after processing by metallo-
proteases [1]. Much has been learned about signal transduc-
tion by Fas (CD95) and by TNF receptor 1 (TNF-R1) [2].
These receptors, and four other members of the family,
TRAIL-R1, TRAIL-R2, TRAMP/DR3 and DR6, contain a
cytoplasmic region, called the death domain, that is essen-
tial for cell death signaling [3,4]. When the receptor is acti-
vated, the death domain undergoes homotypic interaction
with a death domain in the adaptor proteins Fas-associated
death domain protein (FADD) or TNF-receptor-associated
death domain protein (TRADD). FADD binds directly to
Fas and indirectly to TNF-R1 via TRADD but is essential
for cell death signaling from both receptors [2]. The death
effector domain at the amino terminus of FADD recruits
pro-caspase-8 via homotypic interaction with its two death
effector domains. A high local concentration of caspase-8
zymogens is thought to facilitate self-processing and assem-
bly of the mature enzyme. Activated caspase-8 then initiates
apoptosis by cleavage of downstream caspases 3, 6 and 7.
Some γ-herpesviruses and molluscipoxviruses encode a
molecule that has two death effector domains, FLIP; this
protein controls sensitivity towards FasL-mediated apop-
tosis [5,6]. Viral FLIP is recruited via FADD to the Fas
signaling complex and prevents caspase-8 recruitment,
thereby inhibiting apoptosis. Two cellular homologues
have been characterized [7,8]. FLIP(L), the full-length
55 kDa form of FLIP, shows overall structural homology
to caspase-8, containing two death effector domains that
interact with FADD, and an inactive caspase-like domain.
FLIP(S), an alternatively spliced short form of FLIP, con-
tains only the two death effector domains and has lower
anti-apoptotic capacity. 
Because most of the death-domain-containing members of
the TNF receptor family use the adaptor protein FADD to
couple to caspases [2], the finding that T cells without
functional FADD do not proliferate in the presence of
mitogens or on stimulation of the T-cell receptor
(TCR)–CD3 complex was unexpected and suggested that
TCR-induced proliferation of T cells requires activation of
death receptors [9–12]. One of several candidates is Fas, as
TCR stimulation leads to upregulation of FasL [13], and
antibodies to Fas mediate costimulatory signals for T-cell
proliferation [14]. FasL-induced signals also have a dual
role in B cells [15]. FasL is not only essential for triggering
Addresses: *Institute of Biochemistry, University of
Lausanne, BIL Biomedical Research Center,
Chemin des Boveresses 155, CH-1066 Epalinges,
Switzerland. †Immunobiology Program, The
University of Vermont College of Medicine, Given
Medical Building, D-305 Burlington, Vermont
05405-0068, USA.
Correspondence: J. Tschopp
E-mail: jurg.tschopp@ib.unil.ch
Received: 26 October 1999
Revised: 26 January 2000
Accepted: 7 April 2000
Published: 16 May 2000
Current Biology 2000, 10:640–648
0960-9822/00/$ – see front matter 
© 2000 Elsevier Science Ltd. All rights reserved.
B-cell deletion in vivo, but is also required for the promotion
of B-cell clonal proliferation. This switch is modulated by
signals from the B-cell receptor [15]. We undertook a series
of experiments to investigate the mechanisms that allow the
switch from a FasL-induced death pathway to a pathway
that ultimately results in proliferation and/or differentiation.
Results
Recombinant FasL costimulates T-cell growth
Cross-linked soluble FasL added to suboptimal doses of
anti-CD3 antibody promoted a dose-dependent increase
in T-cell growth by as much as fourfold (Figure 1a), con-
firming previous results [14] and indicating that the
reported costimulation of T cells by anti-Fas antibody was
due to the direct activation of proliferative signals and not
merely to blocking of FasL-induced cell death [16]. The
costimulatory effect was similar in size to that of anti-
CD28 antibody (Figure 1a). FasL costimulation was
observed only when soluble FasL was oligomerized
through cross-linking of its FLAG tag by anti-FLAG anti-
body to mimic active membrane-bound FasL [17]. No
proliferation was observed in the absence of the CD3 
costimulatory signal. Cross-talk between the two signaling
pathways is therefore required. 
We further examined signal pathways that might be
involved in Fas costimulation using mice transgenic for
the DNA binding sites of the transcription factors AP-1 or
NF-κB linked to a luciferase gene reporter [18,19]. As in
human T cells, Fas activation by agonistic antibodies
(Figure 1b) or FasL (data not shown) also promoted the
proliferation of CD3-activated T cells from the transgenic
mice and from wild-type mice (data not shown). CD3 acti-
vation of T cells from these mice induced AP-1–luciferase
and NF-κB–luciferase activities that were much increased
in the presence of Fas costimulation (Figure 1c). The 
costimulation was at least as large as that seen with CD28
costimulation. Thus, in primary T cells that are resistant
to Fas-induced death, Fas costimulatory signals enhance
signaling pathways, such as NF-κB and AP-1, that are
important for T-cell growth.
We next examined the point at which FasL-induced
NF-κB and AP-1 signals are diverted from the proapop-
totic pathway which, after Fas oligomerization, is initiated
by FADD recruitment and caspase-8 activation. After 1 h
of stimulation of resting human T cells with anti-CD3
antibody and FasL, partial caspase-8 processing into the
p43 fragment was observed (Figure 1d). During this period
there was no evidence of cell death as detected with pro-
pidium iodide (data not shown). The early appearance of
caspase-8 cleavage during CD3–FasL-induced T-cell acti-
vation in the absence of cell death suggested that a spe-
cific endogenous inhibitor of signals downstream of
caspase-8 might be pivotal in diverting a potential death
signal towards cell growth. The only known endogenous
inhibitor of caspase-8 is FLIP. FLIP(L) acts as a substrate
trap in that it is cleaved by caspase-8 after Asp 376, gener-
ating a 43 kDa fragment [20,21]. FLIP constitutes the first
potential substrate of caspase-8, and its recruitment to the
Fas–FADD–caspase-8 complex can therefore be followed
by monitoring of its proteolytic processing [20,21]. Resting
T cells express predominantly FLIP(L) (Figure 1d and
data not shown). After T-cell activation via anti-CD3 anti-
body and FasL, FLIP was processed to the 43 kDa form
(Figure 1d); this finding suggests that FLIP is involved in
the non-apoptotic Fas signaling pathway. Assembly of the
Fas death-inducing signaling complex [22] (DISC) in pro-
liferating T cells was examined using cross-linked FLAG-
tagged soluble FasL. FLIP was present in the DISC, in
addition to Fas, FADD, and caspase-8 (Figure 1d). Only
the cleaved, processed form of FLIP was detectable in the
DISC. In a previous study, DISC formation was not
observed in short-term activated T cells [21]. In that study,
T cells were analyzed with anti-Fas antibody rather than
FasL after 1 day of phytohaemagglutinin stimulation (and
not directly after TCR/Fas costimulation); this finding
suggests a complex cross-talk between the Fas and TCR
signaling pathways. Thus, under conditions in which FasL
induces not cell death but proliferation, FADD-recruited
FLIP probably binds to caspase-8 thereby stopping further
progression of the death signal. This idea accords with the
previously suggested role of FLIP [7].
FLIP binds components of the NF-κB and Erk signaling
pathways
The observation that FasL-treated resting T cells were not
only resistant to apoptosis but also activated NF-κB and
AP-1 signaling pathways and thus proliferated more vigor-
ously with CD3 costimulation suggested an additional more
active role of FLIP in T-cell signaling than simply as an
inhibitor of apoptosis. We therefore investigated the possi-
bility that FLIP could augment signals that lead to the acti-
vation of these transcription factors. Initially, various forms
of FLIP were expressed in 293T human embryonic kidney
cells (Figure 2). Cotransfection of reporter plasmids with
various FLIP constructs showed that NF-κB could be acti-
vated in a dose-dependent manner by overexpressed
FLIP(L) as well as weakly by FLIP(S), but not by the
carboxy-terminal fragment of FLIP (Figure 2a,b). 
NF-κB activation depends on the formation of a multipro-
tein complex comprising TNF-receptor-associated factors
(TRAFs), NIK, IKKα, IKKβ, NEMO, IκB-α, IκB-β and
IKAP, resulting in phosphorylation and degradation of
IκBα and the release of NF-κB for nuclear translocation
[23,24]. Dominant-negative versions of some of these pro-
teins can block NF-κB-activating signals triggered by
upstream receptors. Indeed, the dominant-negative forms
of IKKβ, TRAF1, and to a lesser extent TRAF2, inhibited
FLIP-mediated NF-κB activation (Figure 2c), indicating
that the overexpression of FLIP initiated NF-κB activation
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upstream of TRAFs. The dominant-negative form of
IRAK1, a kinase implicated in NF-κB signaling induced by
interleukin-1 [25], did not inhibit NF-κB activation. We
found that FLIP interacted with TRAFs 1, 2 and 3, but not
with the other known TRAFs (TRAF4–6) when overex-
pressed in 293T cells (Figure 2d). TRAF1 bound to the
large subunit of the caspase-like region of FLIP (Figure 2e
and data not shown). In addition to TRAFs, the presence
of the serine/threonine kinase RIP is required for the acti-
vation of NF-κB [26]. FLIP was also able to recruit RIP, an
interaction predominantly mediated by the caspase-like
domain (Figure 2f). Thus, FLIP, by virtue of its capacity to
sequester both RIP and TRAFs [27] can recruit proteins
that are involved in IκB degradation.  
In addition to NF-κB, we observed that in 293T cells,
FLIP also spontaneously engaged the signaling pathway
leading to the activation of the mitogen-activated protein
(MAP) kinase Erk (which is ultimately required for AP-1
activation; data not shown). Erk activation is most fre-
quently a result of the Ras-initiated membrane recruit-
ment of the MAP kinase kinase kinase, Raf-1, which leads
to the activation of the MAP kinase kinase, Mek, and then
of Erk. In agreement with this notion, we found that in
293T cells, FLIP bound to Raf-1 (Figure 2g), whereas it
associated only slightly or not at all with activated Ras,
Erk and Mek (data not shown). 
FLIP recruits TRAF1, TRAF2, RIP and Raf-1 to the Fas
signaling complex
As overexpression of proteins in 293T cells can lead to
aberrant protein complex formation that is not found
under physiological conditions, we next wanted to validate
the observed interactions by studying the assembly of the
endogenous proteins. We therefore studied DISC assem-
bly. We analyzed the complex 15 minutes after FasL addi-
tion in mock-transfected and FLIP(L)-transfected Jurkat
T cells [20] (cells destined to undergo apoptosis and cells
that are protected from cell death, respectively). FADD
and caspase-8 were readily coprecipitated from FasL-acti-
vated cells but not from untreated cells (Figure 3a). In
agreement with previous reports [21,22], both pro-caspase-
8 and cleaved caspase-8 were found in the DISC in mock-
transfected, Fas-sensitive cells (Figure 3a). By contrast, in
the DISC isolated from FLIP-expressing cells, we
detected only caspase-8 that had been cleaved between
the large and small subunits of the caspase domain but not
between the death effector domains and the caspase-like
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Figure 1
CD3-induced T cell proliferation is augmented
by FasL and leads to FLIP processing.
(a) Resting human T cells were stimulated
with suboptimal soluble anti-CD3 antibody
(3 µg/ml) in the presence of the indicated
concentrations of soluble FLAG-tagged FasL
(sFasL) with or without cross-linking by
anti-FLAG antibody (1 µg/ml). Proliferation
was monitored by [3H]thymidine incorporation
after 3 days. Error bars show the SD.
(b) Resting murine T cells were stimulated
with suboptimal plastic-immobilized anti-CD3
antibodies at the indicated concentrations in
the presence of agonistic antibodies to Fas or
CD28 (3 µg/ml). (c) CD3/Fas costimulation
of primary murine T cells induced
AP-1–luciferase and NF-κB–luciferase
activities. T cells were purified from mice
transgenic for the DNA binding sites of the
transcription factors AP-1 or NF-κB linked to
a luciferase reporter gene. (d) Resting human
T cells were stimulated with anti-CD3
antibody (3 µg/ml) plus cross-linked soluble
FasL (50 ng/ml). DISC analysis was made after
1 h of culture by adding additional crosslinked
FasL before (+) and after (—) lysis. Western
blots of the DISC or cell lysates are shown.
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domain. Moreover, through the action of caspase-8, DISC-
associated FLIP(L) was completely processed into the
43 kDa form [20–22]. Only the cleaved form of FLIP(L)
was observed in the DISC, despite the presence of similar
amounts of the full-length and the 43 kDa cleaved forms
in the cytoplasm. Incorporation of RIP and TRAF2 into
the DISC was also observed. Recruitment of TRAF2 and
RIP to Fas depended on FLIP, because it was substan-
tially increased in cells overexpressing FLIP. 
To examine whether the interaction between TRAF1 and
FLIP found on overexpression of the protein also
occurred at physiological protein levels, we analyzed
DISC assembly in Raji B cells, which, in contrast to Jurkat
T cells, express TRAF1 (Figure 3b). In addition to TRAF2,
TRAF1 was also detected in the DISC of Raji cells,
whereas TRAF6 (and TRAF3, which is only weakly
expressed; data not shown) was not detectable. There were
also notable other differences in the DISC isolated from
the two cell types. In Raji cells, recruitment of processed
FLIP was very efficient; it was detected even in wild-type
cells that express barely detectable amounts of endogenous
FLIP. The inverse was true for RIP, recruitment of which
was difficult to detect in Raji cells. Moreover, Raf-1 incor-
poration into the DISC was very inefficient, suggesting
that binding was substoichiometric or indirect. We there-
fore studied the time course of DISC assembly
(Figure 3c). Recruitment of Fas, FADD and caspase-8 by
FasL was immediate and detectable as early as 2 minutes
after ligand addition. Maximum DISC formation occurred
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Figure 2
FLIP recruits TRAFs, RIP and Raf-1, and
activates the NF-κB pathway. (a) Human
embryonic kidney 293T cells were
cotransfected with NF-κB luciferase reporter
plasmid, β-galactosidase expression vector and
the FLIP constructs consisting of either 100 ng
FLIP(L), FLIP(S), or the carboxy-terminal portion
of FLIP(L), FLIP(C). Luciferase activities were
determined 24 h after transfection and
normalized on the basis of β-galactosidase
activity. Values shown are averages for
representative experiments in which each
transfection was carried out in duplicate.
Expression of FLIP proteins in the cell extracts
is shown in the lower panel. (b) Dose-response
of the activation of NF-κB by FLIP(L). NF-κB
activation by the IL-1 receptor adaptor protein
MyD88 [36] is shown as a positive control.
(c) Inhibition of FLIP-induced NF-κB activation
by dominant negative (DN)-IKKβ and
DN-TRAF1. 293T cells were cotransfected
with 100 ng FLIP(L) and 0.5 µg DN-IKKβ, DN-
TRAF1, DN-TRAF2, or control DN-IRAK1
expression vectors. Samples were analyzed for
luciferase activity as in (a). (d) 293T cells were
cotransfected with an expression vector for
vesicular stomatitis virus (VSV)-tagged FLIP(L)
and for FLAG-tagged TRAF1–6, as indicated,
and anti-FLAG immunoprecipitates (IP) were
analyzed for the presence of FLIP(L) by
western blotting (WB) using anti-FLIP antibody.
Expression of the FLAG-tagged TRAFs and
VSV-tagged FLIP(L) in the cell extracts is
shown below. (e) The interaction of
haemagglutinin (HA)–TRAF-1 with FLIP was
mapped in 293T cells using FLAG-tagged
FLIP constructs. (f) 293T cells were
cotransfected with expression vectors for
FLAG-tagged FLIP constructs as indicated
as well as for RIP, and anti-FLAG
immunoprecipitates were analyzed for the
presence of RIP. Equal loading is shown by
the IgG band (arrowhead). (g) 293T cells
were cotransfected with an expression vector
for VSV-tagged FLIP(L) and for FLAG-tagged
Raf-1. Anti-FLAG immunoprecipitates were
analyzed for the presence of FLIP(L) by
western blotting using an anti-FLIP antibody.
Expression of the FLAG-tagged Raf-1 and
VSV-tagged FLIP(L) in the cell extracts is
shown below. 
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10–15 minutes after stimulation. Raf-1 (and RIP) recruit-
ment was clearly discernible in the signaling complex of
Raji cells that express exogenous FLIP, whereas in mock-
transfected cells no association was detectable. The kinet-
ics of RIP and Raf-1 recruitment resembled that of
FADD. Taken together, these results suggest a model
whereby FLIP recruitment mediated by Fas and FADD
leads to the further recruitment of proteins that are impor-
tant in signaling pathways activated during Fas-mediated
costimulation of T cells (Figure 1). 
T cells overexpressing FLIP show increased Erk and
NF-κB activation
Given that overexpression of FLIP results in NF-κB and
Erk activation, we investigated whether these two signaling
pathways can also be activated through natural stimuli in a
FLIP-dependent manner. We examined activation of these
signaling pathways in Jurkat cell lines that stably expressed
increased levels of either FLIP(L) or FLIP(S) [20] after
TCR and Fas stimulation. Levels of caspase-8, surface
CD3, and Fas were similar in mock-transfected Jurkat
cells (Jmock) and the FLIP transfectants (data not shown).
After activation by CD3, there was rapid and intense
phosphorylation of IκBα within 15 minutes in FLIP(L)-
transfected Jurkat cells, whereas the response was only
moderate in Jurkat FLIP(S) cells and negligible in control
Jurkat cells (Figure 4a). IκBα phosphorylation was not
affected by the caspase inhibitor z-VAD-fmk (Figure 4b).
In contrast to primary T cells (Figure 1b), no striking
further increase in signal strength was observed when
FasL was added (data not shown). 
After activation of Jurkat cells via CD3, there was also  rapid
phosphorylation of Erk in FLIP-transfected Jurkat cells,
whereas the response in control Jmock cells was insignifi-
cant (Figure 4c). Again, the addition of FasL had no
enhancing effect, perhaps because Jurkat cells are already
actively cycling, or because the rapid surface expression of
FasL (or of another death ligand) upon TCR stimulation is
already optimal [13]. Erk activation was transient, with
maximal activation detectable 15 minutes after stimulation.
There were quantitative differences in the capacities
of FLIP(L) and FLIP(S) to activate the various sig-
naling pathways; FLIP(L) preferentially activated NF-κB
(Figures 4a,2b), but FLIP(S) more strongly activated Erk. 
Erk activation is most frequently a result of the Ras-initi-
ated membrane recruitment of the MAP kinase kinase
kinase Raf-1, which leads to the activation of the MAP
kinase kinase Mek and then Erk. In FLIP-transfected
Jurkat T cells, TCR stimulation also resulted in the activa-
tion of the upstream kinases Mek and Raf-1 (Figure 4c,d).
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Figure 3
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FLIP recruits TRAF1, TRAF2, RIP and Raf-1 to the DISC of Fas.
(a) Wild-type Jurkat cells and Jurkat cells stably transfected with
VSV-FLIP(L) were treated with 2 µg/ml FasL in the presence (+) and
absence (—) of a cross-linking anti-FLAG antibody (2 µg/ml) for
15 min and then lysed. The DISC was then immunoprecipitated using
protein-A–Sepharose. The coimmunoprecipitated Fas, FADD,
caspase-8, FLIP and TRAFs were detected by western blot analysis.
Note that endogenous FLIP is recruited to the DISC although it is not
detectable in the cytoplasm. (b) As (a) except that Raji cells rather
than Jurkat cells were analyzed. Two antibodies to caspase-8 were
used: caspase-8 (N) detects an epitope in the two death effector
domains and recognizes the pro-form and the processed caspase-8
(p43); caspase-8 (C) directed against the small caspase subunit
detects only the pro-form. The right panels show the analysis of
cellular lysates. (c) As (b) but DISC assembly was analyzed after the
indicated time periods. 
The presence of FLIP had no influence on Mek activation
induced by phorbolester (PMA) (Figure 4c), indicating that
the effect of FLIP on Mek activation was linked to TCR
engagement. Since no increased Ras activity was
detectable in FLIP-transfected Jurkat cells with CD3 acti-
vation (Figure 4e), FLIP is likely to be connected to the
Erk pathway at the level of Raf-1. This notion is consistent
with the observed FLIP–Raf-1 interaction (Figure 2g).
To ensure that signals in non-transformed cells were simi-
larly affected by FLIP, transgenic mice were generated that
show increased FLIP expression in T lymphocytes under
the control of the T cell-specific human CD2 enhancer
element [28] (Figure 5a). Stimulation of T-cell blasts from
FLIP transgenic mice via CD3 resulted in the potent acti-
vation of Mek and Erk within 15 minutes (Figure 5b). By
contrast, little activation of the Erk pathway was detected in
cells from non-transgenic littermates. Interestingly, the
presence of increased FLIP expression lead to the spon-
tanous loss of IκBα, reflecting activation of NF-κB, without
further enhancement on TCR stimulation (Figure 5b). A
detailed analysis of FLIP transgenic mice is underway.
Increased interleukin-2 production in cells with increased
FLIP levels
Because Erk/AP-1 and NF-κB, which are activated during
FasL-induced costimulation, are extensively involved in
transcriptional regulation of the T-cell growth factor inter-
leukin-2 (IL-2), production of IL-2 was examined in T
cells derived from FLIP transgenic mice. 24 hours after
activation by either CD3 or CD3 plus CD28, a threefold
increase in IL-2 secretion was measured in stimulated T
cells from FLIP transgenic mice composed with T cells
from non-transgenic littermates (Figure 6a). Similarly,
IL-2 production was consistently increased by sixfold in
Jurkat cells expressing either the FLIP(S) or FLIP(L)
compared with mock-transfected Jurkat cells (Figure 6b).
FLIP thus appears to potentiate TCR signaling pathways
that are required for T-cell proliferation and IL-2 produc-
tion, most likely through its capacity to augment NF-κB
and Erk signaling pathways. 
Discussion
These findings indicate that increased levels of FLIP can
lead to the activation of the Erk and NF-κB signaling
pathways. In T cells, these signals are known to contribute
to IL-2 transcription; indeed, TCR stimulation of acti-
vated T cells bearing increased FLIP levels leads to
increased IL-2 production. Augmented triggering of the
Erk and NF-κB signaling pathways is also detectable in
TCR-stimulated T cells on costimulation with Fas.
How TCR activation leads to FLIP-mediated Erk and
NF-κB signals is currently uncertain. A likely circuit might
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Figure 4
High levels of FLIP mediate activation of the
NF-κB and the Erk pathways in T cells.
(a) FLIP(L) and FLIP(S) Jurkat clones, and a
mock transfectant (Jmock) were stimulated
with immobilized anti-CD3 and anti-CD28
antibodies for 15 min, and NF-κB activation
was assayed by probing for phosphorylated
(–P) IκBα and degradation of IκBα. (b) As
(a) but the experiment was performed in the
presence of 100 µM z-VAD-fmk where
indicated. (c) FLIP-expressing Jurkat clones
were stimulated with immobilized anti-CD3
antibody (1 µg/ml) for the times indicated. Erk
and Mek activation was determined by
western blotting using antibodies specifically
detecting the active phosphorylated (P)
kinases. Expression of total Erk and Mek
proteins was determined using anti-Erk or
anti-Mek antibody, respectively. No increase in
active phosphorylated PKB (Akt) was
discernible (data not shown). In the lower two
panels, Mek activation induced by PMA is
shown. (d) Raf-1 activation in FLIP-expressing
Jurkat cells was assessed 15 min after
stimulation by determining the fraction of
phosphorylated protein that showed lower
electrophoretic mobility (closed arrowhead)
compared with the dephosphorylated form
(open arrowhead). Positive control is Raf-1
activated by PMA (10 ng/ml). (e) Activation of
Ras was determined using recombinant Raf-1
coupled to beads to immunoprecipitate
activated Ras [37]. Positive control are cells
treated with PMA (10 ng/ml). 
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be through the known TCR-induced rapid membrane
exposure of preformed FasL [29] or biosynthesis of FasL
(or of another death ligand), which could then ligate
surface Fas (or other death receptors) and lead to recruit-
ment of FADD and FLIP. This mechanism would be
consistent with our observations and those of others that
exogenous FasL costimulates proliferation with subopti-
mal doses of anti-CD3 antibody, and that CD3-induced
proliferation (which at higher doses becomes FasL-inde-
pendent) is blocked by FasL inhibitors [30]. However,
other death ligands such as TRAIL may also contribute,
since in Jurkat cells, TCR-triggered signal initiation was
only partly blocked by Fas-Fc (data not shown). This may
also indicate differences between primary cells and tumor
cell lines. In any case, activation of Erk and NF-κB signals
in T cells was always dependent on signals emanating
from the TCR and was never observed upon the addition
of FasL alone, even though FasL alone was able to induce
assembly of a complex that included proteins involved in
the two signaling pathways. This suggests a complex
cross-talk of signals. 
Since Erk and NF-κB signals are modulated by FLIP,
levels of this protein may determine the outcome of Fas-
triggered signals. Depending on the ratio of caspase-8
and FLIP levels, Fas-FADD complexes might recruit
either caspase-8 homo-complexes or caspase-8–FLIP
hetero-complexes. In the latter case, FLIP could stop apop-
totic signaling events downstream of caspase-8 activation.
FLIP in turn would act as a platform to recruit TRAF1,
TRAF2, RIP and Raf-1, leading to the simultaneous activa-
tion of the Erk and NF-κB pathways. Thus, FLIP can be
considered as a multifunctional protein, capable of switch-
ing Fas signaling pathways, by blocking progression of
caspase-8 activation and by recruiting adaptor proteins
and kinases that are crucial in the initiation of signaling
pathways leading to proliferation and or differentiation.
This model is similar to what is known about signals trig-
gered by TNF-R1. Addition of TNF can lead to cell
death via TRADD–FADD–caspase-8 or, alternatively, to
activation of NF-κB via TRADD–RIP–TRAF1–TRAF2.
FLIP-induced Erk and NF-κB signals may also help to
explain the observation that the absence of functional
FADD leads to both defective apoptosis and defective
T-cell proliferation [9–12], and is also in agreement with
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Figure 5
Primary T cells from FLIP transgenic mice show increased Erk and
NF-κB activation. (a) Levels of FLAG-tagged transgenic murine FLIP in
splenic T cells from one mouse line was determined with the anti-
FLAG antibody. (b) Anti-CD3-mediated Mek and Erk activation in
T cells from transgenic mice overexpressing FLIP. Purified splenic
T cell blasts from transgenic mice (FLIP TG) and non-transgenic
littermates (control) were stimulated with anti-CD3 antibody for 15 min
and the amount of total and phosphorylated (–P) Mek and Erk, and
total IκBα determined by western blot analysis as in Figure 4. 
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Figure 6
Increased IL-2 production in cells with increased FLIP expression.
Increased IL-2 production by (a) FLIP transgenic T cell blasts and
(b) FLIP-transfected Jurkat clones. Cells were stimulated as
indicated for 24 h and secreted IL-2 in supernatants determined by
the CTLL bioassay [31]. 
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the known decreased IL-2 production by mature T cells
from Fas-deficient lpr mice [31]. 
The switch from Fas–FADD-triggered apoptosis to prolif-
erative signals may be more broadly applicable to other cell
types. Fibroblasts and B cells show increased proliferation
with anti-Fas antibodies or FasL [15,32]. FLIP expression
is increased in many tumor cells [7], suggesting that FasL
expressed on attacking cytolytic T cells may in some cir-
cumstances stimulate tumor cell growth. This hypothesis is
in agreement with recent experiments that show that
FLIP-transfected tumor cell lines escape immune surveil-
lance [33]. Mice deficient in FADD or caspase-8 die at
about day 11 of embryogenesis, presumably as a conse-
quence of abnormal heart development [11,12,34]. Since
FLIP is highly expressed in cardiac myocytes [7,35], and
was found to be deficient in myocardial infarcts [35], FLIP
signals may also be crucial in heart development and func-
tion. Conceivably, through its activation of NF-κB and
Erk, FLIP may be pivotal in turning signals for cell death
into those for cell survival.
Materials and methods
Cell preparation and proliferation
Human peripheral blood lymphocytes were prepared by Ficoll-Hypaque
centrifugation, and T cells were purified by E-rosetting. Cells were cul-
tured in 96-well plates at 5 × 104 cells per well and stimulated with the
indicated concentrations of anti-CD3 antibody (TR66), IgM anti-CD28
antibody (28/34), or soluble recombinant FasL (Alexis) with or without
anti-FLAG antibody (M2, Sigma) at 1 µg/ml. Proliferation was measured
by 3H-thymidine incorporation after 3 days. Murine T cells were prepared
by nylon wool purification from mice transgenic for the DNA binding sites
of AP-1 or NF-κB linked to a luciferase gene reporter [18,19]. T cells
were activated with either plastic immobilized anti-CD3 antibody (145-
2C11) at the indicated concentration, alone or with anti-Fas (Jo2,
5 µg/ml) or anti-CD28 antibody (37.51, 3 µg/ml). Luciferase activity
was measured after 48 h from 2 × 106 cells. Proliferation to the same
stimuli was measured after 3 days in parallel cultures using T cells from
the same mice (5 × 104 cells per well). Splenic T cell blasts from wild-
type or FLIP-transgenic mice were generated via stimulation by plate-
bound anti-CD3 antibody (0.1 µg/ml) and anti-CD28 antibody
(0.3 µg/ml) for 3 days. Supernatants for IL-2 production were taken
from Jurkat T cells (106/ml) or murine splenic T cell blasts (106 /ml) that
were stimulated for 24 h with immobilized anti-CD3 antibody and, when
indicated, with anti-CD28 antibody.
Transfection, immunoprecipitation, Erk and NF-κB activation
assays
FLIP expression clones used in this study have been described
before [20,36]. Stimulated or transfected cells were washed once with
PBS, and lysed in lysis buffer (50 mM Tris–HCl pH 7.5, 1% Triton
X-100, 2 mM DTT, 2 mM sodium vanadate, and protease inhibitor cock-
tail (Complete, Boehringer Mannheim)), followed by centrifugation. Post-
nuclear lysates (30 µg protein) were separated by SDS–PAGE and
analyzed by western blotting. Antibodies were used to the following mol-
ecules: phospho-specific p44/42 MAP kinase (Erk1/Erk2), total P44/42
MAP kinase (Erk1/Erk2), phospho-specific Mek1/2, total Mek1/2,
phospho-specific Jun N-terminal kinase (JNK), phospho-specific IκBα,
total IκBα (all New England Biolabs), FLAG (Sigma), VSV (Babco), Fas
(Alexis). Raf-1 beads were purchased from UBI.
DISC analysis
Purified human T cells and FLIP- and mock-transfected Raji and Jurkat
T cells [20] were treated with 2 µg/ml FasL in the presence or absence
of the cross-linking anti-FLAG M2 antibody (2 µg/ml) for the indicated
times (in the negative control, the cross-linking antibody was added
after lysis). In the case of T cells, cells were prestimulated for 1 h with
anti-CD3 antibody (TR66) and FasL (50 ng/ml) as described above.
Cells were quickly cooled down by adding 5 volumes of ice-cold PBS,
then lysed with 0.2% NP-40, 20 mM Tris–HCl pH 7.4, 150 mM NaCl,
2 mM sodium vanadate, 10% glycerol, and the protease inhibitor cock-
tail. Cytosolic fractions were precleared with Sepharose 6B for 90 min
and then incubated with protein-A- or protein-G-coupled Sepharose
beads for 3 h. Beads were washed four times with the lysis buffer. Pro-
teins were separated on 10% SDS–PAGE, and blotted onto nitrocellu-
lose filters. In control experiments, the anti-FLAG antibody was added
after lysis. The following antibodies were used for western blotting: anti-
Fas (Santa Cruz), anti-FADD (Transduction Labs), anti-caspase 8
(PharMingen, MBL), anti-FLIP AL148 and Dave-2 (Alexis), anti-caspase-
3 (Transduction Laboratories), anti-Raf-1 (PharMingen), anti-RIP (Trans-
duction Labs and PharMingen), anti-TRAF1, 2, 6 (Santa Cruz).
Generation of FLIP transgenic mice
A FLAG-tagged mouse FLIP(L) cDNA sequence was inserted into a tar-
geting vector that contains the β-globin promoter and the CD2 down-
stream locus enhancer element [28]. The resulting construct was
injected into (BALB/c × C57BL/6) embryos, and transgenic founders
were screened by PCR of tail DNA using oligonucleotide primers JT
766 (5′-GGAGCCAGGGCTGGGCATAAAA-3′) and JT767 (5′-GACT-
CACCCTGAAGTTCTCAGGATCC-3′). Expression of the transgene
was further confirmed by western blotting using anti-FLAG antibodies. 
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